Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Fujian Cancer Hospital
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03486496CT.gov Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation | — | Unknown | — | — | — |
NCT00049543CT.gov Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery | — | Completed | — | — | — |
NCT00040794CT.gov Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00020709CT.gov Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lung Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Gefitinib (this asset) | Fujian Cancer Hospital | P3 | BB · 68 |
| Cyclophosphamide | Anusha Kalbasi | P2 | BBB |
| Carboplatin | Guangdong Association of Clinical Trials | P3 | BBB |
| Etoposide | Guangdong Association of Clinical Trials | P3 | BB |
| Nivolumab | Emory University | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Guangdong Association of Clinical Trials | P3 | BB |
| Docetaxel | Sichuan Baili Pharmaceutical Co., Ltd. | P3 | BB |
| Osimertinib | Shanghai Chest Hospital | P2 | BB |
| Vinorelbine Ditartrate | AIO-Studien-gGmbH | P3 | BB |
+42 more in the Lung Adenocarcinoma cohort
Other indications for Gefitinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Central Nervous System Neoplasm | — | P2 | BBB · 73 |
| Gliosarcoma | — | P2 | BB · 71 |
| Lung Large Cell Carcinoma | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Gefitinib in Lung Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/gefitinib-lung-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →